Potential Public Health and Economic Impact of the Next-Generation COVID-19 Vaccine mRNA-1283 in The Netherlands. [PDF]
Vaccines (Basel)van der Pol S +4 more
europepmc +1 more source
Cost-Effectiveness of Tarlatamab in the Second-Line Treatment of Refractory Small Cell Lung Cancer From a US Perspective. [PDF]
Clin Med Insights OncolZheng H, Wen F, Wu B.
europepmc +1 more source
Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer. [PDF]
Front Public HealthJin L, Han L, Zeng J.
europepmc +1 more source
Limb lengthening in achondroplasia: a cost-effectiveness analysis using a Markov model. [PDF]
Orphanet J Rare DisRoza Miguel PO +4 more
europepmc +1 more source
Cost-effectiveness of statins, berberine, and combination for primary cardiovascular disease prevention in Scotland. [PDF]
NPJ Cardiovasc HealthXia Y, Leung K, Zhao JV.
europepmc +1 more source
Cost-Effectiveness of Chondroitin Sulphate (with or without Glucosamine) Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs. [PDF]
Clinicoecon Outcomes ResRubio-Terrés C +2 more
europepmc +1 more source
Economic evaluation of school scoliosis screening in Gannan Tibetan autonomous prefecture, Gansu Province: a cost-utility analysis based on decision tree-Markov model. [PDF]
Front Public HealthYang S +14 more
europepmc +1 more source
Related searches:
When going 'beyond the patient', to measure QALYs for unpaid carers, a number of additional methodological considerations and value judgements must be made. While there is no theoretical reason to restrict the measurement of QALYs to patients, decisions have to be made about which carers to consider, what instruments to use and how to aggregate and ...
Hareth, Al-Janabi +2 more
openaire +2 more sources
A QALY is a QALY is a QALY—or is it not?
2016This chapter looks at a theoretical framework for diversions from the assumption that all units of health gain have equal social value, and examins different ways in which welfarists and non-welfarists may call for cost per weighted QALY analyses, for efficiency-based reasons, and equity-motivated reasons.
John Brazier +3 more
openaire +1 more source
The QALY is the product of life expectancy (estimated in years) and its quality over that time (estimated in utilities or QOL units). It theoretically enables direct comparison of the costs of obtaining different health outcomes through cost utility analysis (CUA).
Maurice, McGregor, J Jaime, Caro
openaire +2 more sources